More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.92B
EPS
-0.43
P/E ratio
--
Price to sales
9.25
Dividend yield
--
Beta
0.61655
Previous close
$7.54
Today's open
$7.30
Day's range
$7.09 - $7.60
52 week range
$2.80 - $9.42
show more
CEO
William E. Martin
Employees
435
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
259938547
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Brendan Smith - TD Cowen, Research Division Justin Bowers - Deutsche Bank AG, Research Division Sean Gardner - UBS Investment Bank, Research Division Jacob Krahenbuhl - William Blair & Company L.L.C., Research Division Matthew Parisi - KeyBanc Capital Markets Inc., Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Hello, and welcome, everyone, joining today's Maravai LifeSciences Q3 2026 Results Earnings Call.
Seeking Alpha • Nov 7, 2026

What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings Call
Maravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at its Cygnus business.
MarketBeat • Nov 5, 2026

Maravai LifeSciences Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates. Key Financial Results: Quarterly revenue of $45.9 million, Net loss of $(24.0) million, and Adjusted EBITDA of $5.8 million; Full year 2026 revenue guidance range increased to $212.0 million to $.
Business Wire • Nov 4, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Maravai LifeSciences Announces November 2026 Investor Conference Schedule
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2026, at 10:40 a.m. EST, Raj Asarpota, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 17, 2026, at 4:00 p.m.
Business Wire • Oct 29, 2026

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4849 or 1-203-518-9848 and reference Marav.
Business Wire • Oct 14, 2026

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5., named "Compositions and Methods for Synthesizing 5'-Capped RNAs." The patent marks TriLink's second granted CleanCap® patent in China within a matter of months, and expands.
Business Wire • Sep 29, 2026

Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel
Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection, with gross margins rising to 40.1% and Adjusted EBITDA turning positive, reflecting successful cost realignment and segment-level improvement. TriLink's integrated GMP enzyme facility and ModTail technology strengthen customer stickiness, while Cygnus provides recurring, high-margin biologics safety earnings.
Seeking Alpha • Sep 2, 2026

Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
MarketBeat • Aug 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Maravai LifeSciences Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.